FDA approved the newest hepatitis B vaccine, Sci-B-Vac, whose clinical trials in Russia were conducted by Pharmsintez. The drug was developed by VBI Vaccines, and Pharmsintez is the exclusive distributor of Sci-B-Vac in Russia. The drug will appear on the Russian market in 2022.
FDA approved the newest hepatitis B vaccine, Sci-B-Vac, whose clinical trials in Russia were conducted by Pharmsintez. The drug was developed by VBI Vaccines, and Pharmsintez is the exclusive distributor of Sci-B-Vac in Russia. The drug will appear on the Russian market in 2022. 
English (US) 